An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels
Overview
- Phase
- Not Applicable
- Intervention
- Neoadjuvant treatment
- Conditions
- Pancreatic Cancer
- Sponsor
- Seoul National University Hospital
- Enrollment
- 1132
- Primary Endpoint
- Overall survival
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Detailed Description
The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
- •Between January 2007 and June 2021 at Seoul National University Hospital
Exclusion Criteria
- •Patients who had borderline resectable PDAC with arterial invasion
- •Patients who received chemotherapy as initial treatment and did not undergo surgery
- •Incomplete follow-up data for analysis
Arms & Interventions
resectable PDAC with no contact to major vessels (R-no contact)
Intervention: Neoadjuvant treatment
resectable PDAC with contact PV/SMV of ≤180° (R-contact)
Intervention: Neoadjuvant treatment
borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)
Intervention: Neoadjuvant treatment
Outcomes
Primary Outcomes
Overall survival
Time Frame: From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months
the time from diagnosis to death from any cause or the date of the last visit